Literature DB >> 3196168

Infection of a human leukemia K-562 cell line with Semliki Forest virus.

D D King1, B Brady, D Dodd, C J Wust, A Brown.   

Abstract

Infection of the human leukemia hematopoietic stem cell line, K-562, with Semliki Forest virus (SFV) can be characterized by three stages: (1) an early virus-proliferating stage lasting 1 to 4 days post-infection (pi) in which infectious virus is produced in high titers (10(3)pfu/cell) but in which there is minimal cytopathic effect. All cells appear viable by trypan blue dye exclusion, although they do not proliferate, and DNA and cell protein synthesis decrease to less than 3% of uninfected controls within 24 hours; (2) an intermediate stage extending from day 5 to about day 24-30 pi in which the amount of infectious virus declines to low levels. During this stage, viral protein synthesis decreases to undetectable levels, although viral gylcoproteins are readily demonstrated by immunofluorescence and by immunoblot; however, capsid protein appears to degrade within 21 days pi. Cell numbers remain constant but the viability of the non-proliferating cells determined by trypan blue exclusion could not be determined with confidence; (3) a final long-term stage in which viral glycoproteins, E1 and E2, are detectable by immunoblots and immunofluorescence for many months but the cells are metabolically inactive and do not synthesize viral proteins. These non-viable cells do not lyse for as long as 2 years.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3196168     DOI: 10.1007/bf01315562

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  32 in total

Review 1.  Properties and usefulness of the original K-562 human myelogenous leukemia cell line.

Authors:  B B Lozzio; C B Lozzio
Journal:  Leuk Res       Date:  1979       Impact factor: 3.156

2.  Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate.

Authors:  J Sutherland; P Mannoni; F Rosa; D Huyat; A R Turner; M Fellous
Journal:  Hum Immunol       Date:  1985-02       Impact factor: 2.850

3.  Natural killer cell resistance in K-562 cell sublines.

Authors:  J S Foster; C J Wust; C B Lozzio; E G Bamberger; A T Ichiki
Journal:  Int J Cancer       Date:  1985-03-15       Impact factor: 7.396

4.  Persistent virus infections in the human myeloid K-562 cell line: genetic implications and practical consequences.

Authors:  C Cernescu
Journal:  Virologie       Date:  1982 Oct-Dec       Impact factor: 0.474

5.  Expression of myeloid-specific antigens on two human erythroleukaemia cell lines, HEL and K562.

Authors:  E F Rimmer; M A Horton
Journal:  Leuk Res       Date:  1984       Impact factor: 3.156

6.  Passive protection across subgroups of alphaviruses by hyperimmune non-cross-neutralizing anti-Sindbis serum.

Authors:  C J Wust; R Crombie; A Brown
Journal:  Proc Soc Exp Biol Med       Date:  1987-01

7.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

8.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

9.  Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

Authors:  D Lovett; B Kozan; M Hadam; K Resch; D Gemsa
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

10.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.